CERUS Corporation needed a partner to supply components for the inactivation of pathogens in platelets and plasma. Porex has collaborated with CERUS, a medical device manufacturer, to develop the INTERCEPT™ Blood System. This innovative system aims to minimize the risk of transfusion-transmitted infections by effectively neutralizing a wide range of pathogens that may be present in donated blood. Porex designed the porous media that integrates the essential functional binder, which is vital for the pathogen inactivation process.
Download the case study to learn more about how POREX developed a technology that would be compatible with the CERUS Corporation system.